Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 6/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.41 |
| ▸ | GSK3A | P49840 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17436086 | 0.85 | CDK5 (0.48) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL15530160 | 0.84 | AURKA (0.40) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL23092822 | 0.79 | TDP2 (0.47) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL29861982 | 0.79 | TDP2 (0.47) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL658962 | 0.78 | AHR (0.53) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL13617978 | 0.78 | AHR (0.37) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL659190 | 0.78 | AHR (0.37) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL659787 | 0.78 | RAB9A (0.40) | AHRCMA1GSK3BGSK3AKDR | |
| SCHEMBL15332656 | 0.75 | AHR (0.35) | AHRCMA1GSK3BCDK5GSK3A | |
| SCHEMBL5502802 | 0.74 | MAPT (0.43) | GSK3BCDK5GSK3AGRM2TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024148191-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024140970-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 广州市联瑞制药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-4371987-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | Gilead Sciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11897878-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-2280953-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | AHR 1727/4885CMA1 4137/4885GSK3B 275/4885 |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | AHR 1727/4885CMA1 4137/4885GSK3B 275/4885 |
| US-11897878-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | AHR 1727/4885CMA1 4137/4885GSK3B 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.